Tuberculosis in patients with haematological malignancies

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 6, Issue 1, 2014, Pages

  Anibarro, Luis ^a,b   Pena, Alberto ^a  

^a Servicio de Medicina Preventiva   (Spain)

^b Hospital Meixoeiro Edificio Anexo   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BENDAMUSTINE; BORTEZOMIB; CAPREOMYCIN; DOXORUBICIN; ETHAMBUTOL; GAMMA INTERFERON; ISONIAZID; KANAMYCIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; VINBLASTINE; VINCRISTINE; RIFAPENTINE;

BACTERIAL VIRULENCE; BACTERIUM IDENTIFICATION; COMBINATION CHEMOTHERAPY; CYTOKINE RELEASE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DRUG ANTAGONISM; DRUG EFFICACY; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; INFECTION PREVENTION; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MOLECULAR PATHOLOGY; MONOTHERAPY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PERSONALIZED MEDICINE; POSTPRIMARY TUBERCULOSIS; PREDICTIVE VALUE; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS; ANTIBIOTIC RESISTANCE; DISEASE COURSE; DRUG RESPONSE; GOLD STANDARD; HEMATOLOGIC DISEASE; IMMUNE RESPONSE; PATHOGENESIS; RISK FACTOR; TH1 CELL;

EID: 84902590067     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2014.026     Document Type: Review

References (101)

1. World, Health, Organization. Global Tuberculosis Report 2013; WHO/HTM/TB/2013.11. Geneva, Switzerland: World Health Organization; 2013.
2. Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med 2013;368:745-55.
3. Grange JM. The genus Mycobacterium and the Mycobacterium tuberculosis complex. In: Schaaf HS ZA, ed. Tuberculosis A comprehensive clinical reference: Elsevier Inc; 2009.
4. Assam Assam JP, Penlap Beng V, Cho-Ngwa F, et al. Mycobacterium tuberculosis is the causative agent of tuberculosis in the southern ecological zones of Cameroon, as shown by genetic analysis. BMC Infect Dis 2013;13:431. http://dx.doi.org/10.1186/1471-2334-13-431
5. Ueyama M, Chikamatsu K, Aono A, et al. Sub-speciation of Mycobacterium tuberculosis complex from tuberculosis patients in Japan. Tuberculosis (Edinb) 2014;94:15-9. http://dx.doi.org/10.1016/j.tube.2013.09.006.
6. de Jong BC, Antonio M, Gagneux S. Mycobacterium africanum--review of an important cause of human tuberculosis in West Africa. PLoS Negl Trop Dis 2010;4:e744.
7. Rodriguez E, Sanchez LP, Perez S, et al. Human tuberculosis due to Mycobacterium bovis and M. caprae in Spain, 2004-2007. Int J Tuberc Lung Dis 2009;13:1536-41.
8. FitzGerald D, Sterling T, Hass D. Mycobacterium tuberculosis. In: Mandell, Douglas, Bennett, eds. Principles and Practice of Infectious Diseases. 7th ed: Churchill Livingstone, Elsevier; 2010:3129-63.
9. Caminero JA. A Tuberculosis Guide for Specialist Physicians: International Union against Tuberculosis and Lung Disease; 2003.
10. Mastorides SM, Oehler RL, Greene JN, Sinnott JT, Kranik M, Sandin RL. The detection of airborne Mycobacterium tuberculosis using micropore membrane air sampling and polymerase chain reaction. Chest 1999;115:19-25. http://dx.doi.org/10.1378/chest.115.1.19
11. Ewer K, Millington K, Deeks J, Alvarez L, Bryant G, Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2006;174:831-9. http://dx.doi.org/10.1164/rccm.200511-1783OC
12. Cardona PJ. A dynamic reinfection hypothesis of latent tuberculosis infection. Infection 2009;37:80-6. http://dx.doi.org/10.1007/s15010-008-8087-y
13. Barrios-Payán J, Saqui-Salces M, Jeyanathan M, et al. Extrapulmonary Locations of Mycobacterium tuberculosis DNA During Latent Infection. Journal of Infectious Diseases 2012;206:1194-205. http://dx.doi.org/10.1093/infdis/jis381
14. Narasimhan P, Wood J, Macintyre CR, Mathai D. Risk factors for tuberculosis. Pulm Med 2013;2013:828939. http://dx.doi.org/10.1155/2013/828939
15. Vynnycky E, Fine PE. Lifetime risks, incubation period, and serial interval of tuberculosis. Am J Epidemiol 2000;152:247-63. http://dx.doi.org/10.1093/aje/152.3.247
16. Russell D, Cardona P, Kim M, Allain S, Altare F. Foamy macrophages and the progression of the human tuberculosis granuloma. Nat Immunol 2009;10:943-8. http://dx.doi.org/10.1038/ni.1781
17. Achkar JM, Jenny-Avital ER. Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response. J Infect Dis 2011;204 Suppl 4:S1179-86 http://dx.doi.org/10.1093/infdis/jir451
18. Esmail H, Barry CE, 3rd, Wilkinson RJ. Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. Drug Discov Today 2012;17:514-21. http://dx.doi.org/10.1016/j.drudis.2011.12.013
19. Pagano L, Caira M, Rossi G, et al. A prospective survey of febrile events in hematological malignancies. Ann Hematol 2012;91:767-74. http://dx.doi.org/10.1007/s00277-011-1373-2
20. Gupta A, Singh M, Singh H, et al. Infections in acute myeloid leukemia: an analysis of 382 febrile episodes. Med Oncol 2010;27:1037-45. http://dx.doi.org/10.1007/s12032-009-9330-9
21. Wu CY, Hu HY, Pu CY, et al. Aerodigestive tract, lung and haematological cancers are risk factors for tuberculosis: an 8-year population-based study. Int J Tuberc Lung Dis 2011;15:125-30.
22. Al-Anazi KA, Al-Jasser AM, Evans DA. Infections caused by Mycobacterium tuberculosis in patients with hematological disorders and in recipients of hematopoietic stem cell transplant, a twelve year retrospective study. Ann Clin Microbiol Antimicrob 2007;6:16. http://dx.doi.org/10.1186/1476-0711-6-16
23. Cliffton EE, Irani BB. Pulmonary tuberculosis and cancer. N Y State J Med 1970;70:274-8.
24. Preventive treatment for tuberculous infection. Recommendations of the National Communicable Disease Center. Arch Environ Health 1970;20:535-6. http://dx.doi.org/10.1080/00039896.1970.10665635
25. Kaplan MH, Armstrong D, Rosen P. Tuberculosis complicating neoplastic disease. A review of 201 cases. Cancer 1974;33:850-8. http://dx.doi.org/10.1002/1097-0142(197403)33:3850::AID-CNCR2820330334>3.0.CO;2-H
26. Stefan DC, Kruis AL, Schaaf HS, Wessels G. Tuberculosis in oncology patients. Ann Trop Paediatr 2008;28:111-6. http://dx.doi.org/10.1179/146532808X302125
27. Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. Clin Infect Dis. United States2006:1592-5.
28. Chen CY, Sheng WH, Lai CC, et al. Mycobacterial infections in adult patients with hematological malignancy. Eur J Clin Microbiol Infect Dis 2011.
29. Libshitz HI, Pannu HK, Elting LS, Cooksley CD. Tuberculosis in cancer patients: an update. J Thorac Imaging 1997;12:41-6. http://dx.doi.org/10.1097/00005382-199701000-00006
30. de la Cámara R, Martino R, Granados E, et al. Tuberculosis after hematopoietic stem cell transplantation: incidence, clinical characteristics and outcome. Spanish Group on InfectiousComplications in Hematopoietic Transplantation. Bone Marrow Transplant 2000;26:291-8. http://dx.doi.org/10.1038/sj.bmt.1702506
31. Mishra P, Kumar R, Mahapatra M, et al. Tuberculosis in acute leukemia: a clinico-hematological profile. Hematology 2006;11:335-40. http://dx.doi.org/10.1080/10245330600915818
32. Chen CY, Sheng WH, Cheng A, et al. Clinical characteristics and outcomes of Mycobacterium tuberculosis disease in adult patients with hematological malignancies. BMC Infect Dis 2011;11:324. http://dx.doi.org/10.1186/1471-2334-11-324
33. Silva FA, Matos JO, de QMFC, Nucci M. Risk factors for and attributable mortality from tuberculosis in patients with hematologic malignances. Haematologica 2005;90:1110-5.
34. Pai M, Denkinger CM, Kik SV, et al. Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection. Clin Microbiol Rev 2014;27:3-20. http://dx.doi.org/10.1128/CMR.00034-13
35. Sokal JE. Editorial: Measurement of delayed skin-test responses. N Engl J Med 1975;293:501-2. http://dx.doi.org/10.1056/NEJM197509042931013
36. Lee E, Holzman RS. Evolution and current use of the tuberculin test. Clin Infect Dis 2002;34:365-70. http://dx.doi.org/10.1086/338149
37. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000;49:1-51.
38. Pai M, Kunimoto D, Frances J, Dick M. Diagnosis of Latent Tuberculosis Infection. Canadian Tuberculosis Standards. 7th ed: Canadian Thoracic Society; 2013
39. Pai M, Riley LW, Colford JM. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004;4:761-76. http://dx.doi.org/10.1016/S1473-3099(04)01206-X
40. Trajman A, Steffen RE, Menzies D. Interferon-Gamma Release Assays versus Tuberculin Skin Testing for the Diagnosis of Latent Tuberculosis Infection: An Overview of the Evidence. Pulm Med 2013;2013:601737. http://dx.doi.org/10.1155/2013/601737
41. Schluger NW. Advances in the diagnosis of latent tuberculosis infection. Semin Respir Crit Care Med 2013;34:60-6. http://dx.doi.org/10.1055/s-0032-1333545
42. Mu-oz L, Santin M. Interferon-? release assays versus tuberculin skin test for targeting people for tuberculosis preventive treatment: an evidence-based review. J Infect 2013;66:381-7. http://dx.doi.org/10.1016/j.jinf.2012.12.005
43. Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-? release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 2012;142:63-75. http://dx.doi.org/10.1378/chest.11-3157
44. Haldar P, Thuraisingam H, Patel H, et al. Single-step QuantiFERON screening of adult contacts: a prospective cohort study of tuberculosis risk. Thorax 2013;68:240-6. http://dx.doi.org/10.1136/thoraxjnl-2011-200956
45. Machingaidze S, Verver S, Mulenga H, et al. Predictive value of recent QuantiFERON conversion for tuberculosis disease in adolescents. Am J Respir Crit Care Med 2012;186:1051-6. http://dx.doi.org/10.1164/rccm.201206-1134OC
46. González-Martín J, García-García J, Anibarro L, et al. [Consensus document on the diagnosis, treatment and prevention of tuberculosis]. Enferm Infecc Microbiol Clin 2010;28:297.e1-20.
47. Redelman-Sidi G, Sepkowitz KA. IFN-? release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med 2013;188:422-31. http://dx.doi.org/10.1164/rccm.201209-1621CI
48. Piana F, Codecasa LR, Cavallerio P, et al. Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J 2006;28:31-4. http://dx.doi.org/10.1183/09031936.06.00110205
49. Richeldi L, Losi M, D'Amico R, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 2009;136:198-204. http://dx.doi.org/10.1378/chest.08-2575
50. Moon SM, Lee SO, Choi SH, et al. Comparison of the QuantiFERON-TB Gold In-Tube test with the tuberculin skin test for detecting latent tuberculosis infection prior to hematopoietic stem cell transplantation. Transpl Infect Dis 2013;15:104-9. http://dx.doi.org/10.1111/j.1399-3062.2012.00765.x
51. Carvalho AC, Schumacher RF, Bigoni S, et al. Contact investigation based on serial interferon-gamma release assays (IGRA) in children from the hematology-oncology ward after exposure to a patient with pulmonary tuberculosis. Infection 2013;41:827-31. http://dx.doi.org/10.1007/s15010-013-0450-y
52. Stefan DC, Dippenaar A, Detjen AK, et al. Interferon-gamma release assays for the detection of Mycobacterium tuberculosis infection in children with cancer. Int J Tuberc Lung Dis 2010;14:689-94.
53. Fountain FF, Tolley E, Chrisman CR, Self TH. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005;128:116-23. http://dx.doi.org/10.1378/chest.128.1.116
54. Anibarro L, Casas S, Paz-Esquete J, et al. Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain. Int J Tuberc Lung Dis 2010;14:701-7.
55. Sánchez-García EM, Gamallo R, Blanco-Moure A, Viejo MA, Amador L, Anibarro L. Toxicity and adherence to treatment for latent tuberculosis infection in patients with hematologic malignancies. Infection 2013;41:903-7. http://dx.doi.org/10.1007/s15010-013-0489-9
56. Chee CB, Sester M, Zhang W, Lange C. Diagnosis and treatment of latent infection with Mycobacterium tuberculosis. Respirology 2013;18:205-16. http://dx.doi.org/10.1111/resp.12002
57. Horsburgh CR, Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med 2011;364:1441-8. http://dx.doi.org/10.1056/NEJMcp1005750
58. Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis 1962;85:490-510.
59. Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis 1967;95:935-43.
60. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-72. http://dx.doi.org/10.1002/art.21043
61. Cruz AT, Ahmed A, Mandalakas AM, Starke JR. Treatment of Latent Tuberculosis Infection in Children. Journal of the Pediatric Infectious Diseases Society 2013;2:248-58. http://dx.doi.org/10.1093/jpids/pit030
62. Snider DE, Caras GJ, Koplan JP. Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. JAMA 1986;255:1579-83. http://dx.doi.org/10.1001/jama.1986.03370120057023
63. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999;3:847-50.
64. Villarino ME, Ridzon R, Weismuller PC, et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med 1997;155:1735-8. http://dx.doi.org/10.1164/ajrccm.155.5.9154885
65. Ziakas P, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis 2009;49:1883-9. http://dx.doi.org/10.1086/647944
66. Spyridis N, Spyridis P, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3-and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007;45:715-22. http://dx.doi.org/10.1086/520983
67. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005;40:670-6. http://dx.doi.org/10.1086/427802
68. Sterling TR, Villarino ME, Borisov AS, et al. Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection. New England Journal of Medicine 2011;365:2155-66. http://dx.doi.org/10.1056/NEJMoa1104875
69. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society ofAmerica. Clin Infect Dis 2011;52:427-31. http://dx.doi.org/10.1093/cid/ciq147
70. Srivastava VM, Krishnaswami H, Srivastava A, Dennison D, Chandy M. Infections in haematological malignancies: an autopsy study of 72 cases. Trans R Soc Trop Med Hyg 1996;90:406-8. http://dx.doi.org/10.1016/S0035-9203(96)90524-6
71. Advani SH, Banavali SD. Pattern of infection in hematologic malignancies: an Indian experience. Rev Infect Dis 1989;11 Suppl 7:S1621-8.
72. (CDC) CfDCaP. Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep 2009;58:7-10.
73. Jagarlamudi R, Kumar L, Kochupillai V, Kapil A, Banerjee U, Thulkar S. Infections in acute leukemia: an analysis of 240 febrile episodes. Med Oncol 2000;17:111-6. http://dx.doi.org/10.1007/BF02796205
74. George B, Mathews V, Srivastava V, Srivastava A, Chandy M. tuberculosis among allogeneic bone marrow transplant recipients in India. Bone Marrow Transplant 2001;27:973-5. http://dx.doi.org/10.1038/sj.bmt.1702993
75. (CDC) CfDCaP. Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep 2009;58:7-10.
76. Achkar JM, Lawn SD, Moosa MY, Wright CA, Kasprowicz VO. Adjunctive tests for diagnosis of tuberculosis: serology, ELISPOT for site-specific lymphocytes, urinary lipoarabinomannan, string test, and fine needle aspiration. J Infect Dis 2011;204 Suppl 4:S1130-41. http://dx.doi.org/10.1093/infdis/jir450
77. Leung CC, Lange C, Zhang Y. Tuberculosis: Current state of knowledge: An epilogue. Respirology 2013;18:1047-55.
78. Mu-oz L, Moure R, Porta N, et al. GeneXpert® for smear-negative pulmonary tuberculosis: does it play a role in low-burden countries? Diagn Microbiol Infect Dis 2013;75:325-6. http://dx.doi.org/10.1016/j.diagmicrobio.2012.11.011
79. Bowles EC, Freyée B, van Ingen J, Mulder B, Boeree MJ, van Soolingen D. Xpert MTB/RIF®, a novel automated polymerase chain reaction-based tool for the diagnosis of tuberculosis. Int J Tuberc Lung Dis 2011;15:988-9. http://dx.doi.org/10.5588/ijtld.10.0574
80. World, Health, Organization. Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system; WHO/HTM/TB/2011.4. Geneva, Switzerland: World Health Organization; 2011.
81. Lawn SD, Dheda K, KerkhoffAD, et al. Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies. BMC Infect Dis 2013;13:407. http://dx.doi.org/10.1186/1471-2334-13-407
82. King AD, Tse GM, Ahuja AT, et al. Necrosis in metastatic neck nodes: diagnostic accuracy of CT, MR imaging, and US. Radiology 2004;230:720-6. http://dx.doi.org/10.1148/radiol.2303030157
83. Chen J, Yang ZG, Shao H, et al. Differentiation of tuberculosis from lymphomas in neck lymph nodes with multidetector-row computed tomography. Int J Tuberc Lung Dis 2012;16:1686-91. http://dx.doi.org/10.5588/ijtld.12.0204
84. Tang SS, Yang ZG, Deng W, Shao H, Chen J, Wen LY. Differentiation between tuberculosis and lymphoma in mediastinal lymph nodes: Evaluation with contrast-enhanced MDCT. Clin Radiol 2012;67:877-83. http://dx.doi.org/10.1016/j.crad.2012.02.006
85. Shao H, Yang ZG, Deng W, Chen J, Tang SS, Wen LY. Tuberculosis versus lymphoma in the abdominal lymph nodes: a comparative study using contrast-enhanced MRI. Eur J Radiol 2012;81:2513-7. http://dx.doi.org/10.1016/j.ejrad.2011.11.004
86. Jung JY, Lim JE, Lee HJ, et al. Questionable role of interferon-? assays for smear-negative pulmonary TB in immunocompromised patients. J Infect 2012;64:188-96. http://dx.doi.org/10.1016/j.jinf.2011.09.008
87. Caminero JA, Matteelli A, Lange C. Treatment of TB. Tuberculosis: European Respiratory Society Journals Ltd; 2012:154-66.
88. World, Health, Organization. Treatment of Tuberculosis Guidelines. WHO/HTM/TB/2009.420. 4th ed. Geneva, Switzerland: World Health Organization; 2010.
89. Clinical diagnosis and management of tuberculosis, and measuresfor its prevention and control. NICE Clinical Guideline 117: National Institute for Health and Clinical Excellence; 2011.
90. Yew WW, Lange C, Leung CC. Treatment of tuberculosis: update 2010. Eur Respir J 2011;37:441-62. http://dx.doi.org/10.1183/09031936.00033010
91. Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin, rifabutin, and rifapentine drug interactions. Current Medical Research and Opinion 2013;29:1-12. http://dx.doi.org/10.1185/03007995.2012.747952
92. http://reference.medscape.com/drug-interactionchecker 2014. (Accessed 28th february 2014
93. World, Health, Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: World Health Organization; 2008.
94. Mitnick C, Bayona J, Palacios E, et al. Community-Based Therapy for Multidrug-Resistant Tuberculosis in Lima, Peru. New England Journal of Medicine 2003;348:119-28. http://dx.doi.org/10.1056/NEJMoa022928
95. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010;10:621-9. http://dx.doi.org/10.1016/S1473-3099(10)70139-0
96. Dheda K, Warren RM, Zumla A, Grobusch MP. Extensively drug-resistant tuberculosis: epidemiology and management challenges. Infect Dis Clin North Am 2010;24:705-25. http://dx.doi.org/10.1016/j.idc.2010.05.001
97. Tang S, Zhang Q, Yu J, et al. Extensively drug-resistant tuberculosis at a tuberculosis specialist hospital in Shanghai, China: clinical characteristics and treatment outcomes. Scand J Infect Dis 2011;43:280-5. http://dx.doi.org/10.3109/00365548.2010.548080
98. O'Donnell MR, Padayatchi N, Kvasnovsky C, Werner L, Master I, Horsburgh CR. Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis 2013;19:416-24. http://dx.doi.org/10.3201/eid1903.120998
99. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:632.
100. Ahmad Khan F, Minion J, Al-Motairi A, Benedetti A, Harries AD, Menzies D. An Updated Systematic Review and Meta-analysis on the Treatment of Active Tuberculosis in Patients With HIV Infection. Clinical Infectious Diseases 2012;55:1154-63. http://dx.doi.org/10.1093/cid/cis630
101. Millet JP, Orcau A, Casals M, Garcia de Olalla P, Caylà JA. Recurrences in tuberculosis in a cohort of human immunodeficiency virus-infected patients: the influence of highly active antiretroviral therapy. Enferm Infecc Microbiol Clin 2013;31:227-9. http://dx.doi.org/10.1016/j.eimc.2012.08.008